Alzheimer Disease & Dementias

The American Academy of Neurology (AAN) recognized several individuals for their achievements, research contributions, service, and commitment to the field of neurology. These award recipients were announced and celebrated at the AAN 2025 Annual Meeting.   

The AAN President’s Award was presented to...

The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These results ...

People with dementia with Lewy bodies (DLB) treated with CT1812 (zervimesine; Cognition Therapeutics, Purchase, NY), an investigational oral therapy, showed significant improvements in cognitive, behavioral, functional, and motor symptoms according to recent results of the phase 2 SHIMMER clinical t...

The emergence of new biomarker tests may enable earlier detection and treatment of symptoms associated with synucleinopathies according to a new comprehensive Clinical Proceedings White Paper published by the Clinical Neurological Society of America (CNSA).

The White Paper, titled “Minimizing the D...

The Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for maintenance dosing with Leqembi (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA). The approval enables patients with early Alzheimer disease (AD) to receive Leqembi treatment by ...

A retrospective chart review published in the Journal of Alzheimer's Disease highlights gaps in diagnosing and managing early Alzheimer disease (AD) in US community-based practices. Researchers found that nearly 1 in 5 patients (16.1%) with early AD did not receive standard neurocognitive assessment...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Leqembi (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA) subcutaneous (SC) autoinjector for weekly maintenance dosing to treat individuals with early Alzheimer disease (AD). The FDA has set a ...

The Diagnostic Evaluation, Testing, Counseling, and Disclosure Clinical Practice Guideline (DETeCD-ADRD CPG) Workgroup, convened and funded by the Alzheimer’s Association, has developed new recommendations for clinicians to use when evaluating patients with possible Alzheimer disease (AD) or AD and ...

Higher cardiorespiratory fitness may be linked to a lower long-term risk of developing dementia, according to data published in the British Journal of Sports Medicine. The results suggest that better cardiorespiratory fitness, as measured by exercise performance on a stationary bicycle, may mitigate...

Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80.

Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorders Center and was a...

A recent study published in Neurology found that stroke survivors have a 76% higher risk of developing dementia compared with those without a history of stroke. The analysis, which evaluated health data from older adults living in Ontario, Canada, found that 18.7% of people with stroke developed dem...

Neflamapimod (CervoMed, Boston, MA) has been granted Orphan Drug Designation by the Food and Drug Administration (FDA) as a potential treatment for individuals with frontotemporal dementia (FTD). Neflamapimod is an orally administered small molecule brain-penetrating inhibitor of p38MAP kinase. Trea...

Frailty measurements may enable the identification of individuals at higher risk of dementia up to 9 years before the onset of the disorder, according to study results published in JAMA Neurology. According to the study authors, the findings demonstrate the potential utility of frailty measurements ...

The Food and Drug Administration (FDA) has granted 510(k) clearance to Icobrain Aria (Icometrix, Boston, MA), a software that provides computer-assisted, automatic detection and severity grading for amyloid-related imaging abnormalities (ARIA). Icobrain Aria generates a quantitative summary report f...

Due to the availability of amyloid-reducing therapies, it is critical to use biomarkers to detect Alzheimer disease (AD) in its early stages, according to a new comprehensive Clinical Proceedings White Paper published by the Clinical Neurological Society of America (CNSA). The white paper titled “Al...